Risk of malignancies associated with ustekinumab

Br J Dermatol. 2018 Jan;178(1):299-300. doi: 10.1111/bjd.16002. Epub 2017 Dec 1.

Authors

A Greenspan¹, P Marty-Ethgen², S Fakharzadeh³

Affiliations

¹ Janssen Scientific Affairs, LLC, Horsham, PA, U.S.A.
² Janssen Research & Development, LLC, Spring House, PA, U.S.A.
³ Janssen Global Services, LLC, Horsham, PA, U.S.A.

PMID: 28940375
DOI: 10.1111/bjd.16002

No abstract available

Publication types

Letter
Comment

MeSH terms

European Union
Humans
Neoplasms
Pharmacovigilance*
United States Food and Drug Administration*
Ustekinumab

Substances

Ustekinumab